Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05583188 · ClinicalTrials.gov registry record · Phase 4
Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC
A Phase 4 study, sponsored by Galvanize Therapeutics.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT05583188: Clinical Trial Phase 4 study, sponsored by Galvanize Therapeutics.
NCT05583188 is a Phase 4 study that was terminated before completion, run by Galvanize Therapeutics. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05583188, a Phase 4 study, was terminated before completion, sponsored by Galvanize Therapeutics.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
A prospective, single-arm, non-randomized, multi-center, open-label study following patients with resectable stage IIB to IIIA non-small cell lung cancer after Pulsed Electric Fields (PEF) ablation who may be candidates for standard of care neoadjuvant use of checkpoint inhibitor (nivolumab) treatment plus platinum doublet chemotherapy.
Primary Outcome
Pathologic response (percentage of residual viable tumor cells) of the resected lesion ablated with PEF and in resected lymph nodes in patients who received standard of care neoadjuvant nivolumab plus chemotherapy prior to resection.
Interventions
- DEVICE Aliya Pulsed Electric Fields (PEF) ablation
- DRUG Nivolumab plus Platinum Doublet Chemotherapy
- DRUG Standard of care neoadjuvant therapy
- OTHER Surgical Resection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2024-03-18 |
| Phase | Phase 4 |
Why NCT05583188 stopped before completion
NCT05583188 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which Aliya Pulsed Electric Fields (PEF) ablation is the first listed.
NCT05583188 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05583188 about?
NCT05583188 is a clinical study titled "Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC". A prospective, single-arm, non-randomized, multi-center, open-label study following patients with resectable stage IIB to IIIA non-small cell lung cancer after Pulsed Electric Fields (PEF) ablation who may be candidates for standard of care neoadjuvant use of checkpoint inhibitor (nivolumab) treatme...
What is the current status of trial NCT05583188?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2023-02-01. Estimated completion is 2024-03-18.
What interventions are being tested in trial NCT05583188?
The interventions under investigation include: Aliya Pulsed Electric Fields (PEF) ablation (DEVICE), Nivolumab plus Platinum Doublet Chemotherapy (DRUG), Standard of care neoadjuvant therapy (DRUG), Surgical Resection (OTHER).
Who is sponsoring clinical trial NCT05583188?
This trial is sponsored by Galvanize Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05583188's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI